COSMO Pharmaceuticals N.V. (COPN) AI Stock Analysis

• Market Cap: CHF1.13B
• Dividend Yield: 2.82%
• Average Volume (3M): 19.52K
• Price to Earnings (P/E): 20.6
• Beta (1Y): 0.98
• Revenue Growth: -3.44%
• EPS Growth: -21.64%
• Country: CH
• Employees: 321
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.12
• Shares Outstanding: 17,543,522
• 10 Day Avg. Volume: 18,700
• 30 Day Avg. Volume: 19,520
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.22
• Price to Sales (P/S): 4.15
• P/FCF Ratio: 7.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF101.00
• Price Target Upside: 50.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: CHF77.00 ▲(14.58% Upside)

COSMO Pharmaceuticals N.V. demonstrates strong financial performance with significant revenue and profit growth, supported by a robust balance sheet and excellent cash flow generation. The technical analysis indicates positive market momentum, while the valuation remains fair, providing a balanced investment opportunity.

Positive Factors

Balance Sheet Health

A low debt-to-equity ratio indicates financial stability, providing the company with flexibility to invest in growth opportunities without the burden of high debt.

Cash Generation Ability

Significant improvement in cash flow generation enhances the company's ability to fund operations, invest in R&D, and pursue strategic initiatives without relying on external financing.

Profit Margin Improvement

Improved profit margins reflect effective cost management and operational efficiency, positioning the company for sustained profitability and competitive advantage in the market.

Negative Factors

Revenue Growth Decline

A decline in revenue growth can signal challenges in market expansion or product adoption, potentially impacting long-term financial performance and strategic objectives.

EPS Growth Decline

A significant decline in EPS growth may indicate operational challenges or increased costs, which could affect investor confidence and the company's ability to generate shareholder value.

Lack of Recent Corporate Events

The absence of recent corporate events or strategic initiatives may suggest a lack of proactive measures to drive growth or adapt to market changes, potentially impacting future competitiveness.

COSMO Pharmaceuticals N.V. Business Overview & Revenue Model

Company Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

How the Company Makes Money

COSMO Pharmaceuticals generates revenue through the commercialization of its proprietary products and licensing agreements with other pharmaceutical companies. Key revenue streams include sales of its developed drugs and medical devices, royalties from partners who utilize its drug delivery technologies, and potential milestone payments from collaborations. The company also engages in strategic partnerships to expand its market reach and enhance its product pipeline, contributing to its overall earnings.

COSMO Pharmaceuticals N.V. Financial Statement Overview

Summary

COSMO Pharmaceuticals N.V. has shown remarkable financial improvements with strong revenue and profit growth. The company maintains a robust balance sheet with minimal debt, high equity, and strong cash flow generation. This financial strength positions the company well for future growth and investment opportunities.

Income Statement

The company demonstrated a significant improvement in financial performance. Gross profit margin improved to 92.56%, and net profit margin rose to 49.94% from negative figures in prior years. Revenue grew by 187.52% from 2023 to 2024, indicating strong operational execution. However, the EBIT and EBITDA margins show a positive trend, reflecting good cost management with EBIT margin at 55.80% and EBITDA margin at 62.11%.

Balance Sheet

The debt-to-equity ratio is low at 0.004, indicating very minimal leverage, which provides financial stability. Return on equity is strong at 26.74%, demonstrating efficient use of equity. The equity ratio is robust at 77.04%, suggesting a strong financial foundation. Overall, the balance sheet reflects a stable financial position with low risk.

Cash Flow

The company's cash flow from operations improved significantly, with a free cash flow growth rate of 755.99% from 2023 to 2024, indicating excellent cash generation capabilities. The operating cash flow to net income ratio is 1.22, and the free cash flow to net income ratio is 1.18, both suggesting strong cash flow in relation to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	182.27M	266.79M	92.78M	102.09M	65.07M	60.95M
Gross Profit	159.99M	246.92M	53.44M	83.33M	49.93M	50.51M
EBITDA	76.31M	165.71M	19.70M	41.17M	17.81M	7.84M
Net Income	55.24M	133.24M	-4.93M	17.23M	21.67M	-7.90M
Balance Sheet
Total Assets	610.33M	646.77M	553.98M	759.59M	805.56M	596.16M
Cash, Cash Equivalents and Short-Term Investments	126.63M	142.96M	50.27M	240.95M	222.21M	212.85M
Total Debt	2.70M	2.20M	1.84M	173.60M	169.92M	168.14M
Total Liabilities	143.35M	141.68M	124.94M	295.80M	292.88M	196.04M
Stockholders Equity	460.24M	498.33M	422.16M	456.93M	505.28M	400.13M
Cash Flow
Free Cash Flow	57.28M	156.76M	18.31M	25.92M	4.11M	4.90M
Operating Cash Flow	64.13M	162.41M	22.71M	33.23M	12.61M	12.98M
Investing Cash Flow	2.59M	-128.88M	42.30M	1.69M	24.86M	75.45M
Financing Cash Flow	-69.06M	-40.22M	-211.27M	-46.13M	-27.25M	-11.88M

COSMO Pharmaceuticals N.V. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 67.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Neutral. The current price of 67.2 is below the 20-day moving average (MA) of 67.46, above the 50-day MA of 65.37, and above the 200-day MA of 58.67, indicating a neutral trend. The MACD of 0.75 indicates Positive momentum. The RSI at 51.82 is Neutral, neither overbought nor oversold. The STOCH value of 69.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:COPN.

COSMO Pharmaceuticals N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COPN	―	CHF1.13B	20.64	11.46%	2.82%	-3.44%	-21.64%
ROG	―	$209.25B	22.04	31.98%	3.72%	4.77%	-11.07%
BSLN	―	CHF584.05M	8.02	―	―	58.51%	―
KURN	―	$1.10B	-183.95	-7.82%	―	104.01%	33.25%
MED	―	CHF1.09B	282.78	―	―	7.29%	-112.70%
MEDX	―	CHF406.43M	―	―	5.17%	-2.42%	-222.68%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

COSMO Pharmaceuticals N.V. Corporate Events

Cosmo Pharmaceuticals Secures EU Approval for Innovative Acne Treatment Winlevi®

Cosmo Pharmaceuticals has received European Commission approval for Winlevi®, a novel acne treatment, marking a significant milestone for the company. This approval allows Cosmo to expand its market presence in Europe, offering a new, effective topical anti-androgen therapy for acne, which is expected to contribute to the company’s growth and provide a much-needed solution for adolescents and adults suffering from acne vulgaris.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in South Korea

Cosmo Pharmaceuticals has achieved a significant milestone with the approval of its acne treatment, Winlevi®, in South Korea by the Ministry of Food and Drug Safety. This approval marks an important step in Cosmo’s global dermatology expansion, highlighting their commitment to innovative, patient-focused therapies. Winlevi® is notable for its unique mechanism as the first topical androgen receptor inhibitor in over four decades, offering a safe and effective treatment for acne vulgaris without systemic anti-androgen effects. The collaboration with Hyundai Pharm Co., Ltd. will facilitate the marketing and distribution of Winlevi® in South Korea, enhancing access to advanced acne treatment options for patients.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Gains CHMP Approval for Winlevi® in Europe

Cosmo Pharmaceuticals has received a positive opinion from the European Medicines Agency’s CHMP for the approval of Winlevi® for treating acne in adults and adolescents in Europe, following a successful re-evaluation. This approval marks a significant expansion for Winlevi® in the European market, offering a novel topical anti-androgen therapy for acne, and is expected to drive Cosmo’s growth across the region.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Extends Global Supply Agreement with Takeda

Cosmo Pharmaceuticals N.V. has extended its strategic production agreement with Takeda for the global supply of Mesalazine MMX 1200 mg, a medication for ulcerative colitis. This extension reinforces Cosmo’s role as a reliable partner in the pharmaceutical industry, highlighting its manufacturing capabilities and commitment to innovation and sustainability. The agreement aligns with Cosmo’s Vision 2030 strategy to expand its leadership position as a CDMO and strengthen its global partnerships.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth Momentum

Cosmo Pharmaceuticals announced that potential US tariffs on Swiss pharmaceutical companies will not impact its operations, as it does not export from Switzerland to the US and has long-term global contracts. The company remains optimistic about its growth trajectory, bolstered by strong fundamentals and increased EBITDA, and continues to deliver stable results to shareholders.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Boosts 2025 EBITDA Guidance Amid Strong H1 Performance

Cosmo Pharmaceuticals reported strong financial results for the first half of 2025, leading to an increase in EBITDA guidance for the full year by EUR 4.5 million. The company experienced significant growth in recurring revenues, particularly from its GI Genius™ and Winlevi® products, and maintained a solid balance sheet. This performance aligns with Cosmo’s ‘Vision 2030’ strategy, emphasizing growth in AI-driven healthcare and specialty pharmaceuticals. The company anticipates continued momentum in the second half of 2025, with expectations of sustained growth in its key sectors, including MedTech AI and dermatology, which are driven by unmet clinical needs.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.